Influence of age on mechanisms and prognosis of heart failure

C. V. Hughes, M. Wong, G. Johnson, J. N. Cohn

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background. Advanced age is commonly thought to carry a poor prognosis in congestive heart failure, but the case has not been established. The Department of Veterans Affairs Cooperative Vasodilator-Heart Failure Trials (V-HeFT I and II) provided a large data base to assess the effect of age on hemodynamic profiles and survival in the failing heart. Methods and Results. Patients were stratified into four categories according to age: ≤55, 56-60, 61-65, and >65 years. The distributions of treatments and baseline characteristics from history, physical findings, and laboratory data were analyzed for differences across age categories. Survival curves were calculated for age strata according to treatment, presence or absence of coronary artery disease, ejection fraction, and peak oxygen consumption. Risk ratios for age and treatment categories showed no consistent trend of treatment effect on mortality. Age was significantly associated with coronary artery disease, hypertension, rhythm disturbances, systolic blood pressure, ejection fraction, and peak oxygen uptake, but successive age strata did not show incremental changes. Survival curves did not show progressively steeper slopes with advancing age. In V-HeFT I, the oldest patients did have the poorest survival, but age interacted with the presence of coronary artery disease and randomization into the placebo group. Conclusions. Contrary to intuitive thinking, age alone did not shorten the survival in congestive heart failure patients who were <75 years old and receiving optimal therapy.

Original languageEnglish (US)
JournalCirculation
Volume87
Issue number6 SUPPL. VI
StatePublished - Jan 1 1993

Fingerprint

Heart Failure
Survival
Coronary Artery Disease
Blood Pressure
Therapeutics
Veterans
Random Allocation
Vasodilator Agents
Oxygen Consumption
Hemodynamics
History
Odds Ratio
Placebos
Databases
Oxygen
Hypertension
Mortality

Keywords

  • aging
  • heart failure, congestive
  • mortality
  • prognosis

Cite this

Hughes, C. V., Wong, M., Johnson, G., & Cohn, J. N. (1993). Influence of age on mechanisms and prognosis of heart failure. Circulation, 87(6 SUPPL. VI).

Influence of age on mechanisms and prognosis of heart failure. / Hughes, C. V.; Wong, M.; Johnson, G.; Cohn, J. N.

In: Circulation, Vol. 87, No. 6 SUPPL. VI, 01.01.1993.

Research output: Contribution to journalArticle

Hughes, CV, Wong, M, Johnson, G & Cohn, JN 1993, 'Influence of age on mechanisms and prognosis of heart failure', Circulation, vol. 87, no. 6 SUPPL. VI.
Hughes CV, Wong M, Johnson G, Cohn JN. Influence of age on mechanisms and prognosis of heart failure. Circulation. 1993 Jan 1;87(6 SUPPL. VI).
Hughes, C. V. ; Wong, M. ; Johnson, G. ; Cohn, J. N. / Influence of age on mechanisms and prognosis of heart failure. In: Circulation. 1993 ; Vol. 87, No. 6 SUPPL. VI.
@article{1dd8995c12bd4649b701409cf3a39cfc,
title = "Influence of age on mechanisms and prognosis of heart failure",
abstract = "Background. Advanced age is commonly thought to carry a poor prognosis in congestive heart failure, but the case has not been established. The Department of Veterans Affairs Cooperative Vasodilator-Heart Failure Trials (V-HeFT I and II) provided a large data base to assess the effect of age on hemodynamic profiles and survival in the failing heart. Methods and Results. Patients were stratified into four categories according to age: ≤55, 56-60, 61-65, and >65 years. The distributions of treatments and baseline characteristics from history, physical findings, and laboratory data were analyzed for differences across age categories. Survival curves were calculated for age strata according to treatment, presence or absence of coronary artery disease, ejection fraction, and peak oxygen consumption. Risk ratios for age and treatment categories showed no consistent trend of treatment effect on mortality. Age was significantly associated with coronary artery disease, hypertension, rhythm disturbances, systolic blood pressure, ejection fraction, and peak oxygen uptake, but successive age strata did not show incremental changes. Survival curves did not show progressively steeper slopes with advancing age. In V-HeFT I, the oldest patients did have the poorest survival, but age interacted with the presence of coronary artery disease and randomization into the placebo group. Conclusions. Contrary to intuitive thinking, age alone did not shorten the survival in congestive heart failure patients who were <75 years old and receiving optimal therapy.",
keywords = "aging, heart failure, congestive, mortality, prognosis",
author = "Hughes, {C. V.} and M. Wong and G. Johnson and Cohn, {J. N.}",
year = "1993",
month = "1",
day = "1",
language = "English (US)",
volume = "87",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "6 SUPPL. VI",

}

TY - JOUR

T1 - Influence of age on mechanisms and prognosis of heart failure

AU - Hughes, C. V.

AU - Wong, M.

AU - Johnson, G.

AU - Cohn, J. N.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Background. Advanced age is commonly thought to carry a poor prognosis in congestive heart failure, but the case has not been established. The Department of Veterans Affairs Cooperative Vasodilator-Heart Failure Trials (V-HeFT I and II) provided a large data base to assess the effect of age on hemodynamic profiles and survival in the failing heart. Methods and Results. Patients were stratified into four categories according to age: ≤55, 56-60, 61-65, and >65 years. The distributions of treatments and baseline characteristics from history, physical findings, and laboratory data were analyzed for differences across age categories. Survival curves were calculated for age strata according to treatment, presence or absence of coronary artery disease, ejection fraction, and peak oxygen consumption. Risk ratios for age and treatment categories showed no consistent trend of treatment effect on mortality. Age was significantly associated with coronary artery disease, hypertension, rhythm disturbances, systolic blood pressure, ejection fraction, and peak oxygen uptake, but successive age strata did not show incremental changes. Survival curves did not show progressively steeper slopes with advancing age. In V-HeFT I, the oldest patients did have the poorest survival, but age interacted with the presence of coronary artery disease and randomization into the placebo group. Conclusions. Contrary to intuitive thinking, age alone did not shorten the survival in congestive heart failure patients who were <75 years old and receiving optimal therapy.

AB - Background. Advanced age is commonly thought to carry a poor prognosis in congestive heart failure, but the case has not been established. The Department of Veterans Affairs Cooperative Vasodilator-Heart Failure Trials (V-HeFT I and II) provided a large data base to assess the effect of age on hemodynamic profiles and survival in the failing heart. Methods and Results. Patients were stratified into four categories according to age: ≤55, 56-60, 61-65, and >65 years. The distributions of treatments and baseline characteristics from history, physical findings, and laboratory data were analyzed for differences across age categories. Survival curves were calculated for age strata according to treatment, presence or absence of coronary artery disease, ejection fraction, and peak oxygen consumption. Risk ratios for age and treatment categories showed no consistent trend of treatment effect on mortality. Age was significantly associated with coronary artery disease, hypertension, rhythm disturbances, systolic blood pressure, ejection fraction, and peak oxygen uptake, but successive age strata did not show incremental changes. Survival curves did not show progressively steeper slopes with advancing age. In V-HeFT I, the oldest patients did have the poorest survival, but age interacted with the presence of coronary artery disease and randomization into the placebo group. Conclusions. Contrary to intuitive thinking, age alone did not shorten the survival in congestive heart failure patients who were <75 years old and receiving optimal therapy.

KW - aging

KW - heart failure, congestive

KW - mortality

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=0027166865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027166865&partnerID=8YFLogxK

M3 - Article

C2 - 8500234

AN - SCOPUS:0027166865

VL - 87

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 6 SUPPL. VI

ER -